Eli Lilly signed a global licensing and co-development agreement with Amylin Pharmaceuticals for AC2993 for the treatment of type 2 diabetes. The deal could be worth up to US$325 M. Eli Lilly also agreed to co-promote Amylin’s Humatrop®, recombinant human growth hormone product.